List of Excipients in Branded Drug PHENTOLAMINE MESYLATE

Generic Drugs Containing PHENTOLAMINE MESYLATE

Company	Ingredient	NDC	Excipient
Hikma Pharmaceuticals USA Inc	phentolamine mesylate	0143-9564	MANNITOL
TAGI Pharma Inc	phentolamine mesylate	51224-012	MANNITOL
Precision Dose Inc	phentolamine mesylate	68094-101	MANNITOL

What are the Most Frequently-Used Excipients in PHENTOLAMINE MESYLATE?

# Of NDCs	Excipient
3	MANNITOL

Phentolamine Mesylate Excipient Strategy and Commercial Opportunities

Last updated: August 9, 2026

Phentolamine mesylate is an off-patent, short-acting alpha-adrenergic antagonist with commercial opportunities concentrated in sterile injectable products, dental anesthesia reversal, hospital extravasation management, and differentiated ready-to-use delivery systems. The strongest product strategy is a preservative-free, low-volume aqueous injection in a cartridge, prefilled syringe, or single-dose vial, supported by robust control of pH, osmolality, sterility, extractables, and container compatibility.

What products contain phentolamine mesylate?

Phentolamine mesylate is marketed primarily as an injectable drug. Its established uses include reversal of soft-tissue anesthesia in dentistry, management of catecholamine-related hypertension, and treatment of vasopressor extravasation.

Product or use	Typical presentation	Commercial relevance
OraVerse	0.4 mg/2 mL dental cartridge	Dental anesthesia reversal
Phentolamine mesylate injection	5 mg single-dose vial or comparable injectable presentation	Hospital and emergency use
Regitine	Historical branded injectable product	Legacy reference product
Compounded topical or local preparations	Variable	Limited, institution-specific use

OraVerse received FDA approval in 2008 for reversal of soft-tissue anesthesia and associated functional deficits following administration of local anesthetics containing a vasoconstrictor. The product is supplied as a sterile, preservative-free solution in a dental cartridge [1].

Phentolamine mesylate is not a biologic. Biosimilar regulation does not apply. Competitive entry is therefore governed by the abbreviated new drug application pathway, 505(b)(2) applications, compounding rules, clinical differentiation, manufacturing economics, and device or presentation advantages.

What is the FDA regulatory status of phentolamine mesylate?

Phentolamine mesylate has an established FDA regulatory history in injectable dosage forms. The regulatory opportunity depends on the target presentation.

Generic injectable pathway

A conventional generic injectable product may rely on pharmaceutical equivalence and bioequivalence principles applicable to parenteral solutions. For a sterile aqueous solution with the same active ingredient, concentration, route, dosage form, and inactive ingredients that do not raise safety concerns, the development burden can be lower than for a new formulation [2].

The principal regulatory requirements include:

• Sterile manufacturing under current good manufacturing practice.
• Demonstration of pharmaceutical equivalence.
• Injectable product quality and stability data.
• Container-closure integrity.
• Particulate and endotoxin controls.
• Extractables and leachables assessment.
• Compatibility with administration components.
• Labeling consistent with the reference product or applicable reference standard.

Dental cartridge pathway

A dental cartridge creates a more specialized opportunity. The product must work with standard dental aspirating syringes and needles while maintaining dose accuracy, cartridge integrity, and resistance to breakage during handling.

The commercial advantages are meaningful:

• Direct fit with existing dental workflows.
• Lower preparation burden than vial-based administration.
• Reduced dosing errors.
• Single-use sterility.
• More efficient chairside storage and dispensing.
• Potential premium over a standard vial despite the same active ingredient.

505(b)(2) pathway

A 505(b)(2) application could support a materially different dosage form or delivery system, such as:

• A ready-to-use prefilled syringe.
• A lower-volume concentrated injection.
• A modified concentration for a defined extravasation protocol.
• A preservative-free multidose system with validated microbial controls.
• A localized delivery product for dental or procedural use.

A 505(b)(2) strategy is more defensible where the product provides a clinically relevant delivery or administration advantage. A simple change in vial size or secondary packaging is less likely to justify a strong regulatory or commercial premium.

What excipients are used in phentolamine mesylate injections?

The excipient system should remain simple. Public labeling for phentolamine products identifies aqueous vehicles and pH-adjusting components, with formulations varying by product and dosage form [1,3].

A practical excipient platform includes:

Excipient function	Candidate materials	Development objective
Tonicity adjustment	Sodium chloride, mannitol	Isotonic or near-isotonic product
Buffering	Sodium acetate/acetic acid or another suitable low-capacity buffer	Maintain target pH without excessive buffer load
Solvent	Water for injection	Parenteral vehicle
pH adjustment	Hydrochloric acid or sodium hydroxide	Final pH control
Antimicrobial preservation	Generally avoid in single-dose products	Reduce toxicity and compatibility risks
Chelation or antioxidant protection	Only if stability data justify use	Control oxidative or trace-metal degradation

The key excipient decision is whether to use sodium chloride, mannitol, or a combination for tonicity. Sodium chloride is cost-effective and familiar in injectable manufacturing. Mannitol can reduce ionic load and may support a different osmolality profile, but it introduces additional crystallization, compatibility, and stability considerations.

What pH and osmolality strategy is appropriate?

Phentolamine mesylate is a salt-form drug intended for aqueous injection. A mildly acidic formulation is generally appropriate for chemical stability and solubility, but the final pH must balance stability with injection-site tolerability.

A development target should address:

• Drug solubility across the intended temperature range.
• Degradation under accelerated and long-term conditions.
• Compatibility with glass and elastomeric closures.
• Local tolerability after subcutaneous or intraoral administration.
• Osmolality in the intended injection volume.
• Risk of precipitation after dilution or contact with other injections.

A low-capacity acetate system may be attractive where the reference product uses acetate-based pH control. Excessive buffering can create tolerability problems and may increase compatibility risks when the product is mixed with other solutions.

The formulation should be evaluated after contact with:

• Polypropylene syringes.
• Cyclic olefin polymer systems.
• Type I glass cartridges.
• Bromobutyl or chlorobutyl stoppers.
• Dental cartridge seals.
• Standard infusion and injection tubing.

Which excipient strategy best supports commercial differentiation?

The most commercially practical strategy is a preservative-free, low-volume solution with a formulation close to the established injectable platform. The differentiation should come from presentation, administration, and supply reliability rather than from a complex excipient system.

Strategy 1: Preservative-free 5 mg vial

This is the lowest-complexity option. It can target hospitals, emergency departments, operating rooms, and oncology units treating vasopressor extravasation.

Potential advantages include:

• Simple formulation.
• Low development cost.
• Broad institutional use.
• Compatibility with established hospital procedures.
• Potential supply opportunity if competitors experience shortages.

The main weakness is limited differentiation. Price competition is likely unless the product offers superior availability, packaging, or contract terms.

Strategy 2: Ready-to-use prefilled syringe

A prefilled syringe could reduce preparation time and dosing error. The product could target emergency departments, procedural areas, and institutions where rapid treatment of extravasation is important.

Development issues include:

• Drug adsorption to syringe components.
• Silicone oil interaction.
• Needle and tip-cap compatibility.
• Shelf-life of the assembled device.
• Shipping impact and break-loose force.
• Dose accuracy at low fill volumes.

A prefilled syringe is more commercially defensible than a standard vial but has higher device, stability, and combination-product complexity.

Strategy 3: Dental cartridge

The dental cartridge is the strongest presentation-specific opportunity. A cartridge-based generic or alternative product could compete directly with OraVerse if it achieves equivalent performance and reliable dental distribution.

Critical attributes include:

• Standard cartridge dimensions.
• Compatibility with aspirating dental syringes.
• Low extractables and leachables.
• Resistance to stopper movement.
• Accurate fill volume.
• Minimal headspace.
• Reliable crimp and seal integrity.
• Clear labeling to avoid confusion with local anesthetic cartridges.

A dental cartridge can support premium pricing because the value is tied to workflow integration rather than active ingredient novelty.

Strategy 4: Dual-use institutional presentation

A product designed for both dental and hospital use may reduce manufacturing complexity, but the dosing and labeling requirements differ. A 0.4 mg/2 mL dental presentation is not a direct substitute for a 5 mg hospital vial.

The better approach is a platform with common bulk formulation and separate fill-finish configurations. This can reduce formulation development expense while preserving market-specific packaging.

What formulation patents protect phentolamine mesylate?

Phentolamine mesylate is an old active pharmaceutical ingredient, and the core composition-of-matter patent estate is not commercially relevant. The principal intellectual-property risks are more likely to arise from:

• Specific dental cartridge designs.
• Device components.
• Novel prefilled syringe systems.
• Stabilized injectable formulations.
• Combination products.
• Use claims tied to a particular clinical setting.
• Manufacturing processes with narrow claim scope.

OraVerse was approved in 2008, and any ordinary regulatory exclusivity associated with the original approval has expired. The product is therefore exposed to generic competition from a regulatory exclusivity perspective [1,2].

Current Orange Book analysis should distinguish between:

1. Active listed patents.
2. Expired patents.
3. Delisted patents.
4. Patent certifications associated with generic applications.
5. Device or packaging patents not listed in the Orange Book.

The Orange Book does not provide a complete freedom-to-operate analysis for formulation, manufacturing, cartridge, syringe, or device claims. A company pursuing a differentiated presentation must review U.S. patent records separately from FDA listing data [2,4].

When does phentolamine mesylate lose exclusivity?

Phentolamine mesylate has already lost meaningful market exclusivity for its established injectable uses. The product is an off-patent small molecule, and regulatory barriers are substantially lower than for a recently approved drug.

Exclusivity category	Status
Composition-of-matter exclusivity	Expired
Standard small-molecule patent term	Expired for the original active ingredient
Original NDA exclusivity for OraVerse	Expired
Biosimilar exclusivity	Not applicable
Generic entry risk	High for standard injectable products
Presentation-specific protection	Potentially relevant for cartridges, syringes, and devices

The commercial question is not whether the molecule remains protected. It is whether a new product can create enough value through presentation, supply, distribution, or workflow integration to avoid commodity pricing.

What generic entry risks exist for phentolamine mesylate?

Generic entry risk is highest for standard single-dose vials. Buyers can often substitute products based on active ingredient, concentration, route, and dosage form.

The main competitive risks are:

• Multiple ANDA applicants entering the vial market.
• Hospital purchasing committees selecting the lowest-cost supplier.
• Contract manufacturing reducing barriers to entry.
• Institutional substitution after formulary review.
• Low switching costs for experienced pharmacy departments.
• Limited clinical differentiation between conventional injectable solutions.

The risk is lower for a dental cartridge because the product must satisfy format, device, distribution, and workflow requirements. A manufacturer with established dental sales channels may have an advantage over a hospital-generic company.

Which companies are positioned to compete?

Competition can arise from several groups:

Generic injectable manufacturers

These companies compete on:

• FDA-approved sterile manufacturing.
• Contract pricing.
• Hospital distribution.
• Shortage response.
• Vial and carton configurations.

Dental pharmaceutical companies

Dental manufacturers have stronger access to:

• Dental distributors.
• Group practices.
• Academic dental centers.
• Office-based procedural users.
• Cartridge production and packaging expertise.

Contract development and manufacturing organizations

CDMOs can enable entry by providing:

• Aseptic fill-finish.
• Cartridge filling.
• Prefilled syringe assembly.
• Sterility testing.
• Stability programs.
• Small-to-medium commercial batches.

The most credible entrant is likely to combine an approved sterile manufacturing platform with dental or institutional distribution. A molecule-only strategy without channel access is less attractive.

What licensing deals could support a phentolamine product?

Licensing opportunities are more likely to involve technology and distribution than active-ingredient rights.

Potential deal structures include:

Deal type	Licensed asset	Commercial purpose
Dental distribution agreement	Cartridge product and regional rights	Rapid market access
CDMO agreement	Sterile fill-finish and packaging	Reduce capital expenditure
Device license	Prefilled syringe or cartridge system	Accelerate differentiated presentation
Hospital channel agreement	Institutional sales and formulary access	Secure recurring demand
Regional commercialization license	Country-specific approvals	Expand geographic coverage
Manufacturing technology license	Cartridge filling or container closure	Improve reliability and scale

A license should be evaluated for territorial rights, regulatory ownership, supply obligations, minimum purchase commitments, change-control authority, and shortage remedies. Because the active ingredient is generic, the defensible value normally sits in the product configuration and commercial channel.

How strong is the patent estate for phentolamine mesylate?

The core patent estate is weak because the active ingredient and established injectable use are old. A new entrant should not assume that phentolamine mesylate itself supports meaningful exclusivity.

Patent strength may be moderate only where claims cover:

• A narrowly defined excipient ratio.
• A validated stability improvement.
• A cartridge or syringe architecture.
• A specific delivery device.
• A manufacturing process that produces a measurable quality advantage.
• A new method of use with credible clinical differentiation.

Formulation patents face common validity risks. Broad claims covering a simple aqueous solution, ordinary tonicity agents, or routine pH adjustment may be vulnerable to obviousness and lack-of-inventive-step challenges. Stronger claims require comparative data showing unexpected stability, tolerability, shelf life, or device performance.

What manufacturing and IP barriers affect market entry?

Sterile manufacturing is the principal operational barrier. The active ingredient is inexpensive, but the product requires validated aseptic processing and a reliable container-closure system.

Key barriers include:

• Small-volume sterile filling.
• Cartridge or syringe assembly.
• Low-dose content uniformity.
• Particulate control.
• Extractables and leachables.
• Long-term stability in the final package.
• Supply of pharmaceutical-grade phentolamine mesylate.
• Qualification of elastomeric components.
• Reliable cold-chain or controlled-room-temperature distribution.
• Dental device compatibility.

Geographic expansion adds country-specific requirements for sterile products, pharmacopoeial standards, packaging, and local registration. The U.S. market offers the clearest regulatory precedent, while Europe and other jurisdictions may require separate development of dental cartridge and hospital-use presentations.

What are the strongest commercial opportunities?

The most attractive opportunities rank as follows:

1. A reliable generic dental cartridge with established dental distribution.
2. A ready-to-use prefilled syringe for hospital extravasation protocols.
3. A shortage-resistant 5 mg single-dose vial.
4. A regional product manufactured through a qualified sterile CDMO.
5. A differentiated cartridge or syringe with validated stability and handling advantages.

A standard vial can generate revenue but is likely to face price pressure. A dental cartridge has better potential for gross-margin protection because it solves a workflow problem. A prefilled syringe may command a premium if hospitals value rapid administration and reduced preparation risk.

Key Takeaways

• Phentolamine mesylate is an off-patent small molecule with no biosimilar pathway.
• The principal opportunities are sterile injectable products, dental cartridges, and ready-to-use syringes.
• A simple preservative-free aqueous formulation is the most practical starting platform.
• Sodium chloride, mannitol, acetate-based pH control, water for injection, and pH adjusters are the main excipient options.
• The strongest commercial differentiation comes from packaging, device compatibility, supply reliability, and distribution.
• Standard vials face high generic substitution and price competition.
• Dental cartridges offer stronger workflow-based differentiation than conventional vials.
• Core composition-of-matter exclusivity is expired; new patent value would need to come from formulation, device, manufacturing, or method-of-use claims.
• Sterile fill-finish and container-closure performance are greater entry barriers than the active ingredient.
• Licensing targets are most likely to involve dental distribution, CDMO capacity, cartridge technology, or prefilled-syringe platforms.

Frequently Asked Questions

Can phentolamine mesylate be formulated without preservatives?

Yes. Single-dose injectable products should generally use a preservative-free formulation where feasible. This approach reduces preservative toxicity, compatibility, and labeling concerns.

Is a phentolamine mesylate dental cartridge patentable?

Potentially, but patentability would usually depend on the cartridge system, formulation performance, or a non-obvious combination of drug concentration, excipients, container materials, and delivery characteristics. The active ingredient alone does not provide new patent protection.

Is phentolamine mesylate suitable for a prefilled syringe?

Yes, provided that adsorption, silicone oil interaction, closure integrity, particulate formation, dose accuracy, and long-term stability are demonstrated in the selected syringe system.

Does phentolamine mesylate qualify for biosimilar competition?

No. Phentolamine mesylate is a synthetic small molecule. Competitors would generally pursue generic or 505(b)(2) pathways rather than biosimilar approval.

What is the best commercial dosage form for a new entrant?

A preservative-free dental cartridge is the strongest differentiated option. A 5 mg vial is simpler to develop but is more exposed to institutional generic pricing and substitution.

References

1. U.S. Food and Drug Administration. (2008). OraVerse (phentolamine mesylate) injection, prescribing information. FDA.

2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: The Orange Book. FDA.

3. DailyMed. (2024). Phentolamine mesylate injection: Product labeling. National Library of Medicine.

4. U.S. Patent and Trademark Office. (2024). Patent Public Search. U.S. Department of Commerce.